Evaluation of Angiotensin II in Patients With Catecholamine-Resistant Vasodilatory Shock Requiring Continuous Renal Replacement Therapy (ANGEL CRRT).

Objective: To compare clinical outcomes of patients with catecholamine-resistant vasodilatory shock (CRVS) receiving continuous renal replacement therapy who receive adjunctive angiotensin II (ANGII) to those who do not.

Design: Retrospective cohort analysis.

Setting: Multicenter, single health system consisting of one academic medical center and four community hospitals.